IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 34.5% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 100,603 shares of the medical research company’s stock after acquiring an additional 25,778 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.06% of IQVIA worth $23,840,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. FMR LLC increased its position in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares in the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new position in IQVIA during the third quarter worth approximately $147,683,000. 1832 Asset Management L.P. lifted its stake in IQVIA by 472.3% in the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after buying an additional 376,595 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of IQVIA in the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc grew its position in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock worth $344,998,000 after acquiring an additional 264,555 shares during the last quarter. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

NYSE:IQV opened at $200.96 on Friday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The firm’s fifty day simple moving average is $218.67 and its 200-day simple moving average is $226.20. The stock has a market cap of $36.47 billion, a PE ratio of 26.37, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51.

Analyst Ratings Changes

Several analysts recently commented on IQV shares. Leerink Partners reiterated an “outperform” rating and issued a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Morgan Stanley reduced their target price on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, November 4th. TD Cowen lowered their price target on IQVIA from $270.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Royal Bank of Canada reaffirmed an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Friday, November 1st. Finally, BTIG Research lowered their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Five analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $256.50.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.